Diabetes enhances the expression of H-ras and suppresses the expression of EGFR leading to increased cell proliferation

Histology and Histopathology

Volumn 24, Issue 5, 2009, Pages 531-539

  Vairaktaris, Eleftherios ^a   Goutzanis, Lampros ^a   Yapijakis, Christos ^a   Vassiliou, Stavros ^a   Spyridonidou, Sofia ^a   Vylliotis, Antonis ^a   Nkenke, Emeka ^b   Lazaris, Andreas C ^a   Strantzias, Pashalis ^a   Patsouris, Efstratios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

c fos; Diabetes; EGFR; H ras; Oral squamous cell carcinoma

Indexed keywords

ANIMALIA; RATTUS;

4 NITROQUINOLINE 1 OXIDE; CARCINOGEN; EGFR PROTEIN, RAT; EPIDERMAL GROWTH FACTOR RECEPTOR; HRAS PROTEIN, RAT; ONCOPROTEIN; PROTEIN C FOS; RAS PROTEIN;

ANIMAL; ARTICLE; CELL PROLIFERATION; EXPERIMENTAL DIABETES MELLITUS; FEMALE; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUTH TUMOR; PATHOLOGY; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; SQUAMOUS CELL CARCINOMA;

4-NITROQUINOLINE-1-OXIDE; ANIMALS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; IMMUNOHISTOCHEMISTRY; MAP KINASE SIGNALING SYSTEM; MOUTH NEOPLASMS; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; RAS PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 67149111805     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Crowe D.L., Hacia J.G., Hsieh C.L., Sinha U.K. and Rice H. (2002). Molecular pathology of head and neck cancer. Histol. Histopathol. 17, 909-914.
2. Das B.R. and Nagpal J.K. (2002). Understanding the biology of oral cancer. Med Sci Monit. 8, RA258-267.
3. Das N., Majumder J. and Dasgupta U.B. (2000). ras gene mutations in oral cancer in eastern India. Oral Oncol. 36, 76-80.
4. De Sousa S.O., Mesquita R.A., Pinto D.S. Jr and Gutkind S. (2002). Immunolocalization of c-Fos and c-Jun in human oral mucosa and in oral squamous cell carcinoma. J. Oral Pathol. Med. 31, 78-81.
5. Derka S., Vairaktaris E., Papakosta V., Vassiliou S., Acil Y., Vylliotis A., Spyridonidou S., Lazaris A.C., Mourouzis C., Kokkori A., Moulavasili P., Perrea D., Donta I., Yapijakis C. and Patsouris E. (2006). Cell proliferation and apoptosis culminate in early stages of oral oncogenesis. Oral Oncol. 42, 540-550.
6. Ekberg T., Nestor M., Engstrom M., Nordgren H., Wester K., Carlsson J. and Anniko M. (2005). Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int. J. Oncol. 26, 1177-1185.
7. Finney L.S., Finney M.O. and Gonzales Campoy J.M. (1997). What the mouth has to say about diabetes. Careful examinations can avert serious complications. Postgrad. Med. 102, 117-126.
8. Fisher W.E., Muscarella P., Boros L.G. and Schirmer W.J. (1998). Variable effect of streptozotocin-diabetes on the growth of hamster pancreatic cancer (H2T) in the Syrian hamster and nude mouse. Surgery 123, 315-320.
9. Forastiere A., Koch W., Trotti A. and Sidransky D. (2001). Head and neck cancer. N. Engl. J. Med. 345, 1890-1900.
10. Friedman J.E., Ishizuka T., Liu S., Farrell C.J., Bedol D., Koletsky R.J., Kaung H.L. and Ernsberger P. (1997). Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am. J. Physiol. 273, E1014-1023.
11. Goutzanis L., Vairaktaris E., Yapijakis C., Kavantzas N., Nkenke E., Derka S., Vassiliou S., Acil Y., Kessler P., Stavrianeas N., Perrea D., Donta I., Skandalakis P. and Patsouris E. (2007). Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway. Oral Oncol. 43, 165-173.
12. Junod A., Lambert A.E., Stauffacher W. and Renold A.E. (1969). Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J. Clin. Invest. 48, 2129-2139.
13. Karin M. (1995). The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270, 16483-16486.
14. Kawamura M., Fukuda S., Kawabata K. and Iwamoto Y. (1998). Comparison of health behaviour and oral/medical conditions in noninsulin-dependent (type 2) diabetics and non diabetics. Austr. Dent. J. 43, 315-320.
15. Khan A.J., Fligiel S.E., Liu L., Jaszewski R., Chandok A. and Majumdar A.P. (1999). Induction of EGFR tyrosine kinase in the gastric mucosa of diabetic rats. Proc. Soc. Exp. Biol. Med. 221, 105-110.
16. Korc M., Matrisian L.M., Nakamura R. and Magun B.E. (1984). Epidermal growth factor binding is altered in pancreatic acini from diabetic rats. Life Sci. 35, 2049-2055.
17. Kowluru R.A., Kowluru A., Chakrabarti S. and Khan Z. (2004). Potential contributory role of H-ras, a small G-protein, in the development of retinopathy in diabetic rats. Diabetes 53, 775-783.
18. McDonald J.S., Jones H., Pavelic Z.P., Pavelic L.J., Stambrook P.J. and Gluckman J.L. (1994). Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck. J. Oral Pathol. Med. 23, 342-346.
19. Miettinen P.J., Ustinov J., Ormio P., Gao R., Palgi J., Hakonen E., Juntti-Berggren L., Berggren PO. and Otonkoski T. (2006). Downregulation of EGF receptor signaling in pancreatic islets causes diabetes due to impaired postnatal beta-cell growth. Diabetes 55, 3299-3308.
20. Milde-Langosch K. (2005). The Fos family of transcription factors and their role in tumourigenesis. Eur. J. Cancer 41, 2449-2461.
21. Munirajan A.K., Mohanprasad B.K.C., Shanmugam G. and Tsuchida N. (1998). Detection of a rare point mutation at codon 59 and relatively high incidence of H-ras mutation in Indian oral cancer. Int. J. Oncol. 13, 971-974.
22. Ohyama M., Hirayama Y., Tanuma J.I., Hirano M., Semba I., Shisa H., Hiai H., Sugihara K. and Kitano M. (2004). Expressions of junB and c-fos are enhanced in 4-nitroquinoline 1-oxide-induced rat tongue cancers. Pathol. Int. 54, 35-40.
23. Okamoto M., Kahn C.R., Maron R. and White M.F. (1988). Decreased autophosphorylation of EGF receptor in insulindeficient diabetic rats. Am. J. Physiol. 254, 429-434.
24. Olayioye M.A., Neve R.M., Lane H.A. and Hynes N.E. (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19, 3159-3167.
25. Rikimaru K., Tadokoro K., Yamamoto T., Enomoto S. and Tsuchida N. (1992). Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck. Head Neck 14, 8-13.
26. Rogers S.J., Harrington K.J., Rhys-Evans P. and O-Charoenrat P. (2005). Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metast. Rev. 24, 47-69.
27. Sakata K. (1996). Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma. J. Oral Pathol. Med. 25, 302-307.
28. Sankaranarayanan R., Masuyer E. and Swaminathan R. (1998). Head and neck cancer: a global perspective on epidemiology and survival. Anticancer Res. 18, 4779-4786.
29. Santini J., Formento J.L., Francoual M., Milano G., Schneider M., Dassonville O. and Demard F. (1991). Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13, 132-139.
30. Saranath D., Chang S.E., Bhoite L.T., Panchal R.G., Kerr I.B., Mehta A.R., Johnson N.W. and Deo M.G. (1991). High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br. J. Cancer 63, 573-578.
31. Sissom J.F., Stenzel W.K. and Warshaw J.B. (1987). Decreased binding of epidermal growth factor in placentas from streptozotocin-diabetic rats. J. Clin. Invest. 80, 242-247.
32. Sudbo J., Bryne M., Johannessen A.C., Kildal W., Danielsen H.E. and Reith A. (2001). Comparison of histological grading and large-scale genomic status (DNA ploidy) as prognostic tools in oral dysplasia. J. Pathol. 194, 303-313.
33. Todd R. and Wong DT. (1999). Epidermal growth factor receptor (EGFR) biology and human oral cancer. Histol. Histopathol. 14, 491-500.
34. Todd R., Donoff R.B. and Wong D.T.W. (1997). The molecular biology of oral cancer: toward a tumour progression model. J. Oral Maxillofac. Surg. 55, 613-623.
35. Turatti E., Da Costa Neves A., De Magalhaes M.H. and De Sousa S.O. (2005). Assessment of c-Jun, c-Fos and cyclin D1 in premalignant and malignant oral lesions. J. Oral Sci. 47, 71-76.
36. Ujpal M., Matos O., Bibok G., Somogyi A., Szabo G. and Suba Z. (2004). Diabetes and oral tumors in Hungary. Epidemiological correlations. Diabetes Care 27, 770-774.
37. Ujpal M., Matos O., Bibok G. and Szabo G. (2002). Incidence of diabetes mellitus in patients with malignant tumors of the oral cavity. Orv. Hetil. 143, 2731-2733.
38. Vairaktaris E., Goutzanis L., Kalokerinos G., Yannopoulos A., Yapijakis C., Vassiliou S., Spyridonidou S., Vylliotis A., Nkenke E., Lazaris A., Tesseromatis C. and Patsouris E. (2007). Diabetes increases both N-ras and ets-1 expression during rat oral oncogenesis resulting in enhanced cell proliferation and metastatic potential. In Vivo 21, 615-621.
39. Wang P.H., Almahfouz A., Giorgino F., McCowen K.C. and Smith R.J. (1999). In vivo insulin signaling in the myocardium of streptozotocindiabetic rats: Opposite effects of diabetes on insulin stimulation of glycogen synthase and c-Fos. Endocrinology 140, 1141-1150.
40. Warnakulasuriya K.A.A.S., Chang S.E. and Johnson N.W. (1992). Point mutations in the Ha-ras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinomas, but are infrequent in British cases. J. Oral Pathol. Med. 21, 225-229.
41. Wells A. (1999). EGF receptor. Int. J. Biochem. Cell. B. 31, 637-643.
42. Werkmeister R., Brandt B. and Joos U. (1996). The erbB oncogenes as prognostic markers in oral squamous cell carcinomas. Am. J. Surg. 72, 681-683.
43. Werkmeister R., Brandt B. and Joos U. (2000). Clinical relevance of erbB-1 and-2 oncogenes in oral carcinomas. Oral Oncol. 36, 100-105.
44. Xia W., Lau Y.K., Zhang H.Z., Xiao F.Y., Johnston D.A., Liu A.R., Li L., Katz R.L. and Hung M.C. (1999). Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin. Cancer Res. 5, 4164-4174.
45. Xu J., Gimenez-Conti I.B., Cunningham J.E., Collet A.M., Luna M.A., Lanfranchi H.E., Spitz M.R. and Conti C.J. (1998). Alterations of p53, cyclin D1, Rb and H-ras in human oral carcinomas related to tobacco use. Cancer 83, 204-212.
46. Yeudall W.A., Torrance L.K., Elsegood K.A., Speight P., Scully C. and Prime S.S. (1993). Ras gene point mutation is a rare event in premalignant tissues and malignant cells and tissues from oral mucosal lesions. Eur. J. Cancer B. Oral Oncol. 29B, 63-67.
47. Ziyadeh F.N. and Goldfarb S. (1991). The renal tubulointerstitium in diabetes mellitus. Kidney Int. 39, 464-475.